#Abs0588 Effectiveness of TNFi vs non-TNFis in obese patients with #rheumatic disease @MilenaGianfran: 👉🏼>16000pts @ACRheum RISE 👉🏼Abatacept➡️larger decreases in CDAI in obese pts 👉🏼Tocilizumab➡️larger decreases in CDAI in non-obese pts @RheumNow #ACR21 https://t.co/bL5xnG1iNh

• Effectiveness of TNFi versus Non-TNFi Biologics on Disease Activity in Obese Pa…

Does #comorbidity burden affect treatment of #InflammatoryArthritis? Abs#0577 #ACR21 👉🏼~6500pts; 11 types of IA 👉🏼Higher comorbidity burden➡️more likely to receive steroids than TNFis 👉🏼Are patients w/ IA & multiple comorbidities receiving suboptimal therapy? @RheumNow #ACRBest https://t.co/iIERb0wL4Y

Predictors of clinical remission in AS patients Rx with TNFi ⭐️Age and 3-mo BASDAI improvement➡️ predictor of clinical remission criteria ⭐️Normalized ESR and CRP at month 3 were predictors of achievement of BASDAI-CRP Abst#0931 #ACR21 @RheumNow https://t.co/Ot1ypgNg3A

Baseline/ Clinical /Imaging predictors of flare when tapering TNFI in axSpA in remission: ⭐️🔼Baseline physician global VAS 🔼flare in 16 weeks after tapering to 2/3 of standard dose. ⭐️🔼Age 🔼flare within 16 weeks after tapering to 1/2 dose Abst #0929 #ACR21 @RheumNow https://t.co/EFiwKA8z99

Turkish study finds that ETN may be negatively associated w/ the development of ADA in AS pts. Abs 0936 #ACR21 #RheumNow @RheumNow https://t.co/z3pYDpp1NN https://t.co/MR1R41rCHV

• Factors Associated with the Development of Anti-drug Antibodies to Tumour Necro…

Evaluate effectiveness and Rx survival of different TNFI in cohort of axSpA ⭐️No difference among different TNFI ⭐️No difference between nr-axSpA and AS ⭐️Failure to initial TNFI did not diminish effectiveness or drug survival of subsequent TNFi Rx Abst#0938 #ACR21 @RheumNow

#ACR21 Abst#0588. TNF vs non-TNFi in obese RA pts ⭐️TNFi use ⬆️ disease activity vs ABA in obese pts ⭐️TNFi use ⬆️ activity vs TCZ in non-obese pts ⭐️No diff w RTX, Tofa ▶️Further research needed: Wt-based dosing? SC vs IV? https://t.co/K8WycPTgxW @Rheumnow #ACRBest

• https://bit.ly/3H1GMDI

ORAL Surveillance MACE conclusions: So this is fair: tofacitinib acts as a CV risk factor, there are many others, we need to address CV risk in RA pts. Nevertheless, in terms of MI risk, tofa vs TNFi, if I had one CV risk factor, I know what I'd do. #ACR21 ABST0958 @RheumNow https://t.co/4Z79XtTzl9

Let's look at MI first. Well, the numbers don't look great for tofa here. fatal MI very small numbers non-fatal MI - well that doesn't look good (do we have combined both tofa doses vs TNFi?) HR > 2 seems less than ideal - this would represent a substantial RF #ACR21 @RheumNow https://t.co/5HSXFrMJCu

ORAL Surveillance: MACE events higher in TOFA vs TNFi. Independent risk factors: smoking, aspirin use, age ≥ 65 yrs, and male sex; TOFA vs TNFi tx in these pts assoc'd w/ numerically higher MACE incidence. Plenary Abs 0958 #ACR21 #ACRbest @RheumNow https://t.co/44af1KujqP

• Risk Factors for Major Adverse Cardiovascular Events in Patients Aged ≥ 50 Year…